Ticagrelor vs. Clopidogrel in Post PCI Patients

NCT ID: NCT05858918

Last Updated: 2023-05-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 476 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-10-01
• Study Completion Date: 2023-03-01

Brief Summary

Elective PCI were included in the study. Patients were randomized into two different groups. One group took ASA 80 mg once daily and clopidogrel 75 mg once a day, and the other one took ASA 80 mg once a day and ticagrelor 90 mg twice a day. After six months of close follow-up, patients were asked to give a score to their dyspnea and asked about the major advance cardiovascular events ( MACE)

Detailed Description

Clinical data of this Randomized Clinical Trial (RCT) study was gathered from patients referred to Prof. Kojuri cardiovascular clinic (Shiraz, Iran, Email: kojurij@yahoo.com , webpage: http://kojuriclinic.com/ ) from October 2022 to March 2023. The inclusion criterion was experiencing elective percutaneous coronary intervention (PCI). Patients diagnosed with hypersensitivity to either ticagrelor or clopidogrel or the ones having any other contraindications such as active pathological bleeding, were excluded from the study. Patients who consumed anticoagulants in the course of their medical therapy were also excluded.

Basic clinical information of all patients such as diabetes mellitus (diagnosed based on ADA 2018 criteria [23]), hypertension (defined as systolic blood pressure > 130 mmHg or diastolic blood > 80 mmHg based on 2017 ACC/AHA hypertension guideline [24]), dyslipidemia, anemia (defined according to 1968 Who definition [25]), asthma (diagnosed based on 2007 NAEPP criteria [26]) , chronic obstructive pulmonary disease (diagnosed according to 2020 GOLD criteria [27]), and atrial fibrillation (AF) were recorded. Furthermore, other clinical data such as body mass index (normal; 18.5 to 24.9, overweight; 25 to 29.9 and obesity; higher than 30), left ventricle ejection fracture (LVEF), and heart failure (classified based on 2001 ACC/AHA heart failure classification [28]), history of using tobacco within the past 3 months, and past drug history were also recorded. Major bleeding was defined according to the Thrombolysis in Myocardial Infarction (TIMI) criteria: intracranial bleeding, hemorrhage with a hemoglobin decrease of at least 5 g/dL, or fatal bleeding that caused death within 7 days [29].

Patients were asked to give a score to their dyspnea based on the 10 point Likert scale before undergoing PCI. Score 1-3 were considered mild, score 4-7 were considered moderate, and score 7-10 were considered severe. Patients were randomized using the Block randomization method with block size=4 into two different groups. One group took acetylsalicylic acid (ASA) 80 mg once daily and clopidogrel 75 mg that is produced by Sanofi company available in market as Plavix once a day, and the other one took ASA 80 mg once a day and ticagrelor 90 mg that is produced by Abidi company available in market as Brilavus twice a day.

The patients were completely informed about the advantages and disadvantages of the study, and inform consents were taken from participants. Patients who desired not to participate were excluded from the study. Participants were told to take their medications regularly, and they were also encouraged to call us immediately if they faced any medical problem for further investigation.

After six months of close follow-up, patients were asked to give a score to their dyspnea happened after PCI, based on the 10 point Likert scale. They were also asked about having dyspnea on exertion, paroxysmal nocturnal dyspnea (PND), any bleeding such as GI bleeding, and occurrence of major adverse cardiovascular event (MACE; defined as acute coronary syndrome (ACS), stroke, revascularization, hospitalization due to heart failure, and cardiac death.) [29] We followed the patients by using their phone numbers which were obtained at the beginning of the study.

For statistical analyses we used IBM SPSS software version 25. Independent-sample t tests and one-way ANOVA were used for parametric variables. The Mann-Whitney U test and Kruskal-Wallis test were used for nonparametric data. Values of p <0.05 were considered significant.

The study protocol was based on Helsinky declaration, all patients were filled the written consent, The study protocol was approved by Ethical committee of Shiraz University of medical sciences under the number of IR.SUMS.MED.REC.1401.351.

Conditions

Stable Chronic Angina

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

clopidogrel

patient post elective angioplasty and stenting receiving aspirin 80 mg and clopidogrel 75 mg PO daily

Group Type: ACTIVE_COMPARATOR

Clopidogrel

Intervention Type: DRUG

Treatment with dual antiplatelet drug,aspirin 80 mg PO daily with clopidogrel 75 mg PO daily

ticagrelor

patient post elective angioplasty and stenting receiving aspirin 80 mg and ticagrelor 90 mg PO twice daily

Group Type: ACTIVE_COMPARATOR

Ticagrelor

Intervention Type: DRUG

Treatment with dual antiplatelet drug,aspirin 80 mg PO daily with ticagrelor 90 mg PO twice daily

Interventions

Clopidogrel

Treatment with dual antiplatelet drug,aspirin 80 mg PO daily with clopidogrel 75 mg PO daily

Intervention Type: DRUG

Ticagrelor

Treatment with dual antiplatelet drug,aspirin 80 mg PO daily with ticagrelor 90 mg PO twice daily

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Experiencing elective percutaneous coronary intervention (PCI).

Exclusion Criteria

• Patients diagnosed with hypersensitivity to either ticagrelor or clopidogrel
• Active pathological bleeding
• Patients who consumed anticoagulants in the course of their medical therapy

• Minimum Eligible Age: 50 Years
• Maximum Eligible Age: 76 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shiraz University of Medical Sciences

OTHER

Sponsor Role: lead

Responsible Party

Javad Kojuri

professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Professor Kojuri Cardiology Clinic

Shiraz, , Iran

Countries

Iran

References

Mehdizadeh Parizi M, Golchin Vafa R, Ahmadi A, Heydarzade R, Sadeghi M, Khademolhossseini A, Amiri F, Khoshnood Mansorkhani S, Tavan A, Hosseini N, Montaseri M, Hosseini SA, Kojuri J. Comparison of Ticagrelor and Clopidogrel in Elective Coronary Stenting: A Double Blind Randomized Clinical Trial. J Interv Cardiol. 2023 Dec 26;2023:5544440. doi: 10.1155/2023/5544440. eCollection 2023.

Reference Type: DERIVED

PMID: 38170033 (View on PubMed)

Other Identifiers

IR.SUMS.MED.REC.1401.351

Identifier Type: -

Identifier Source: org_study_id